4 July 2024 - Referred by the Ministry of Health, the High Authority for Health has assessed the opportunity to integrate the newly authorized Arexvy and Abrysvo vaccines into the strategy for preventing respiratory syncytial virus infections in the elderly. 

A respiratory syncytial virus infection in this population is likely to lead to serious complications that can lead to death. The HAS recommends vaccination of the most vulnerable: people aged 75 and over as well as people aged 65 and over with chronic respiratory or cardiac pathologies.

Read Haute Authorité de Santé press release